down arrow

Yield10 Bioscience, Inc.

  • Market Cap: N/A
  • Industry: Chemicals & Petrochemicals
  • ISIN: US98585K8624
USD
0.00
0.00 (0.00%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.69
Valuation
Technical
Day's Volume

CASH

48

Shareholding (Jun 2024)

FII

0.11%

Held by 3 FIIs

DII

98.8%

Held by 1 DIIs

Promoter

0.00%

How big is Yield10 Bioscience, Inc.?

22-Jun-2025

As of Jun 13, Yield10 Bioscience, Inc. has a market capitalization of 0.01, classifying it as a Micro Cap company, with net sales of 0.75 million and a net profit of -12.71 million over the last four quarters. As of Dec 23, the company reported shareholder's funds of -2.48 million and total assets of 3.91 million.

Market Cap: As of Jun 13, Yield10 Bioscience, Inc. has a market capitalization of 0.01, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Yield10 Bioscience, Inc. reported net sales of 0.75 million and a net profit of -12.71 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of -2.48 million and total assets of 3.91 million.

Read More

Who are in the management team of Yield10 Bioscience, Inc.?

22-Jun-2025

As of March 2022, the management team of Yield10 Bioscience, Inc. includes Chairman Robert Van Nostrand, CEO Dr. Oliver Peoples, and Directors Dr. Sherri Brown, Dr. Richard Hamilton, Mr. Joseph Shaulson, and Dr. Anthony Sinskey. They are responsible for the company's strategic direction.

As of March 2022, the management team of Yield10 Bioscience, Inc. includes the following individuals:<BR><BR>- Mr. Robert Van Nostrand, Chairman of the Board and Independent Director<BR>- Dr. Oliver Peoples, President, Chief Executive Officer, and Director<BR>- Dr. Sherri Brown, Director<BR>- Dr. Richard Hamilton, Director<BR>- Mr. Joseph Shaulson, Director<BR>- Dr. Anthony Sinskey, Independent Director<BR><BR>This team is responsible for guiding the strategic direction of the company.

Read More

Is Yield10 Bioscience, Inc. overvalued or undervalued?

25-Jun-2025

Yield10 Bioscience, Inc. is considered overvalued with a negative P/E ratio and EV to EBITDA, reflecting poor financial performance, and its current price of $0.01 is significantly lower than its 52-week high of $2.33, especially when compared to more attractive peers like CVR Partners LP and Oil-Dri Corp. of America.

As of 8 March 2018, Yield10 Bioscience, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is considered overvalued given its negative financial ratios, including a P/E ratio of -0.0008 and an EV to EBITDA of -0.08, both of which reflect a lack of profitability and operational efficiency. The current price of $0.01 is a stark contrast to its 52-week high of $2.33, highlighting the substantial decline in market perception.<BR><BR>In comparison to peers, Yield10 Bioscience's valuation metrics are notably poor. For instance, CVR Partners LP is rated very attractive with a P/E of 12.50, while Oil-Dri Corp. of America shows a strong P/E of 22.31. This stark contrast underscores the challenges Yield10 faces in attracting investor interest. Additionally, the company's year-to-date return of -95.19% compared to the S&P 500's 2.44% reinforces the notion that it is significantly overvalued in the current market environment.

Read More

Is Yield10 Bioscience, Inc. technically bullish or bearish?

20-Sep-2025

As of February 11, 2025, Yield10 Bioscience, Inc. shows a mildly bearish trend with mixed signals across indicators, including mildly bullish MACD readings, bearish daily moving averages, and a significant year-to-date decline of 99.97%.

As of 11 February 2025, the technical trend for Yield10 Bioscience, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages remain bearish, and the Bollinger Bands show a sideways trend on the weekly and mildly bearish on the monthly.<BR><BR>The KST indicates a mildly bullish stance on the weekly but is bearish on the monthly, and both the Dow Theory and OBV show no trend in either time frame. <BR><BR>Yield10 has experienced significant declines, with a year-to-date return of -99.97% compared to a 12.22% gain in the S&P 500, highlighting a stark underperformance. Overall, the current technical stance is mildly bearish with mixed signals across different indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Chemicals & Petrochemicals

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.15

stock-summary
Return on Equity

203.62%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2024)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-99.33%
0%
-99.33%
1 Year
-99.98%
0%
-99.98%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Yield10 Bioscience, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Yield10 Bioscience, Inc. technically bullish or bearish?

As of 11 February 2025, the technical trend for Yield10 Bioscience, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages remain bearish, and the Bollinger Bands show a sideways trend on the weekly and mildly bearish on the monthly. The KST indicates a mildly bullish stance on the weekly but is bearish on the monthly, and both the Dow Theory and OBV show no trend in either time frame. Yield10 has experienced significant declines, with a year-to-date return of -99.97% compared to a 12.22% gain in the S&P 500, highlighting a stark underperformance. Overall, the current technical stance is mildly bearish with mixed signals across different indicators....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
1.92%
EBIT Growth (5y)
-12.42%
EBIT to Interest (avg)
-10.93
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.02
Tax Ratio
1.02%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.51%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
-0.00
EV to EBIT
-0.08
EV to EBITDA
-0.08
EV to Capital Employed
-0.18
EV to Sales
0.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.09%)

Foreign Institutions

Held by 3 Foreign Institutions (0.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 13.51% vs -8.82% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.10",
          "val2": "-3.60",
          "chgp": "13.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.20",
          "val2": "-3.70",
          "chgp": "13.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7,117.80%",
          "val2": "0.00%",
          "chgp": "-711.78%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -75.00% vs -33.33% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -6.62% vs -23.64% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.40",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.10",
          "val2": "-12.80",
          "chgp": "-10.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.50",
          "val2": "-13.60",
          "chgp": "-6.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-240,283.30%",
          "val2": "-29,891.10%",
          "chgp": "-21,039.22%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'24 - YoYstock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.40
0.00
Operating Profit (PBDIT) excl Other Income
-3.10
-3.60
13.89%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.20
-3.70
13.51%
Operating Profit Margin (Excl OI)
-7,117.80%
0.00%
-711.78%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2024 is 13.51% vs -8.82% in Jun 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.10
0.40
-75.00%
Operating Profit (PBDIT) excl Other Income
-14.10
-12.80
-10.16%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-14.50
-13.60
-6.62%
Operating Profit Margin (Excl OI)
-240,283.30%
-29,891.10%
-21,039.22%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -75.00% vs -33.33% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -6.62% vs -23.64% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Yield10 Bioscience, Inc. stock-summary
stock-summary
Yield10 Bioscience, Inc.
Chemicals & Petrochemicals
Yield10 Bioscience, Inc., formerly Metabolix, Inc., is an agricultural bioscience company. The Company is focused on developing disruptive technologies for step-change improvements in crop yield for food and feed crops to enhance global food security. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism to direct more carbon to seed production, the Company is advancing several yield traits it has developed in crops, such as Camelina, canola, soybean and corn. The Company concentrates on technologies that enables it to improve carbon dioxide fixation efficiency in photosynthesis and its direction to and conversion into plant matter. The Company has an additional agricultural science facility with greenhouses in Saskatoon, Saskatchewan, Canada.
Company Coordinates stock-summary
Company Details
19 Presidential Way Ste 201 , WOBURN MA : 01801-1184
stock-summary
Tel: 1 617 5831700
stock-summary
http://www.yield10bio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."